Featured Research

from universities, journals, and other organizations

Researchers Working To Improve Treatments For Injured Soldiers

Date:
March 21, 2007
Source:
University of Missouri-Columbia
Summary:
Improvised explosive devices (IEDs) are often to blame when soldiers are wounded in Iraq and Afghanistan. The makeshift weapons account for a high percentage of musculoskeletal injuries that, in both theaters, frequently lead to difficult-to-treat infections. Military physicians have faced challenges treating such infections, and the US Army has turned to a University of Missouri-Columbia research physician to study the problem and develop medical solutions.

Improvised explosive devices (IEDs) are often to blame when soldiers are wounded in Iraq and Afghanistan. The makeshift weapons account for a high percentage of musculoskeletal injuries that, in both theaters, frequently lead to difficult-to-treat infections. Military physicians have faced challenges treating such infections, and the U.S. Army has turned to a University of Missouri-Columbia research physician to study the problem and develop medical solutions.

"The bacteria weˇ¦re seeing is quite different than what weˇ¦re used to dealing with," said Jason Calhoun, J. Vernon Luck Distinguished Professor and chair of the MU School of Medicineˇ¦s Department of Orthopaedic Surgery. "Many are resistant to common types of antibiotics."

Calhoun has been awarded a $1.6 million grant from the U.S. Army Institute of Surgical Research to study infections that are multi-drug resistant. He is partnering with Walter Reed Army Medical Center and Brooke Army Medical Center to build a database on veterans with infections and study how those infections could be better treated.

In Iraq and Afghanistan, Calhoun said about 70 percent of all injuries involve extremities. That statistic is higher than in past conflicts due to significant advances in protective body armor, he said. In addition, about half of those with extremity injuries develop significant infections that require additional treatment and surgery, which often leads to amputation, Calhoun said.

During a four-year period, lab tests will be conducted at MUˇ¦s medical school to simulate blast wounds and examine four types of infections that have become increasingly common among those injured in action. The bacteria being studied include: Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Staphylococcus aureus.

Calhoun will:

  • identify antibiotics that can effectively treat those bacteria;
  • determine when antibiotics should be administered after an injury; and
  • determine an effective duration of antibiotic treatment to reduce the growth of resistant strains.

The study will give the Army guidance on how field medics can better administer antibiotics to injured troops. Calhoun said some of the infections occur naturally because of bacteria common to the region, such as soil contamination following the injury. Others result from intentional acts by opposing forces ˇV devices which purposely contain harmful agents like manure and chemicals, he said.

"Every war is different, but this one is different because of the amount of explosive devices that our soldiers are encountering," Calhoun said. "In the last few months, there has been an increase in the tonnage of those devices, and the blast injuries are even worse. Over the past three years, many of our soldiers have had open fractures where the soft tissue is injured and the bone is injured, and there is significant contamination of that tissue. Many of those soldiers go on to develop a severe infection of their extremity. Ultimately this research could mean fewer extremity infections, fewer surgeries and fewer amputations."

He also is optimistic the advances can benefit the U.S. civilian population and lead to improved treatments for injuries occurring in automobile and farm accidents.


Story Source:

The above story is based on materials provided by University of Missouri-Columbia. Note: Materials may be edited for content and length.


Cite This Page:

University of Missouri-Columbia. "Researchers Working To Improve Treatments For Injured Soldiers." ScienceDaily. ScienceDaily, 21 March 2007. <www.sciencedaily.com/releases/2007/03/070319175857.htm>.
University of Missouri-Columbia. (2007, March 21). Researchers Working To Improve Treatments For Injured Soldiers. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2007/03/070319175857.htm
University of Missouri-Columbia. "Researchers Working To Improve Treatments For Injured Soldiers." ScienceDaily. www.sciencedaily.com/releases/2007/03/070319175857.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins